Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 NCT02735707

anticoagulant, curative dose (n=1190) vs. anticoagulant, prophylactic dose (n=1054)

randomized controlled trial   some concerns about risk of bias

Studied treatment

therapeutic-dose anticoagulation with heparin

Control treatment

usual care pharmacological thromboprophylaxis

Patients

COVID-19 mild to moderate

Method

open-label

prematurely discontinued after a planned adaptive analysis of data from 1398 patients showed that the prespecified stopping criteria for superiority of therapeutic-dose anticoagulation had been reached in both the high and low d-dimer cohorts

Remark